SHIRE NPS PHARMACEUTICALS INC has a total of 81 patent applications. Its first patent ever was published in 2005. It filed its patents most often in United States, Taiwan and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals, medical technology and biotechnology are INTERCELL USA INC, PSMA DEV COMPANY L L C and TG THERAPEUTICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 51 | |
#2 | Taiwan | 5 | |
#3 | WIPO (World Intellectual Property Organization) | 5 | |
#4 | Australia | 4 | |
#5 | Canada | 4 | |
#6 | Argentina | 2 | |
#7 | Brazil | 2 | |
#8 | China | 2 | |
#9 | EPO (European Patent Office) | 2 | |
#10 | Israel | 2 | |
#11 | Republic of Korea | 1 | |
#12 | Luxembourg | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Medical technology | |
#3 | Biotechnology | |
#4 | Organic fine chemistry | |
#5 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Diagnosis and surgery | |
#4 | Peptides | |
#5 | Acyclic or carbocyclic compounds | |
#6 | Analysing materials | |
#7 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Marriott Thomas B | 50 |
#2 | Lopansri Jennifer | 50 |
#3 | Blosch Consuelo M | 50 |
#4 | Sanguinetti Elizabeth L | 50 |
#5 | Norton Angela | 19 |
#6 | Strack-Logue Bettina | 16 |
#7 | Pan Clark | 15 |
#8 | Sun Kefeng | 5 |
#9 | Souillac Pierre | 4 |
#10 | Olivier Clement | 4 |
Publication | Filing date | Title |
---|---|---|
US2020247865A1 | Parathyroid hormone variants | |
US2020121761A1 | Treatment of short bowel syndrome patients with colon-in-continuity | |
WO2020086741A1 | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions | |
AU2019315807A1 | Formulations for improved stability of recombinant human parathyroid hormone | |
KR20200085763A | GLP-2 analogs and peptibody for pre-operative, post-operative or post-operative administration | |
TW201919684A | Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers | |
CA3071966A1 | Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions |